

薬物療法	Question	PubMed検索式
BQ1	ホルモン受容体陽性乳癌に対して、内分泌療法は有用か？	("Breast Neoplasms/drug therapy"[MH] AND "Chemotherapy, Adjuvant"[MH] AND(("Antineoplastic Agents, Hormonal"[MH] OR "Antineoplastic Agents, Hormonal" [PA]) OR ("Aromatase Inhibitors"[MH] OR "Aromatase Inhibitors" [PA]) OR ("Estrogen Antagonists"[MH] OR "Estrogen Antagonists" [PA]) OR "Gonadotropin-Releasing Hormone"[MH] OR "Tamoxifen"[MH] OR ("Letrozole"[MH] OR "Anastrozole"[MH] OR "exemestane" [NM] OR ("Nitriles"[MH] OR "Triazoles"[MH]) AND ("2016"[DP] : "2019"[DP]))) AND (english[LA] OR japanese[LA]) AND ("2016/01"[DP] : "2021/03"[DP]))
BQ2	タモキシフェンは子宮内膜癌（子宮体癌）発症のリスクを増加させるか？	((("Endometrial Neoplasms"[MH] OR ("breast neoplasms"[MH] AND ("endometrial"[TIAB] OR "Endometrium"[TIAB]))) AND "tamoxifen"[MH] AND ("english"[LA] OR "japanese"[LA]) AND 2016/01/01:2021/03/31[DP]) AND (humans[MH]))
CQ1	ホルモン受容体陽性非浸潤性乳管癌に対して乳房部分切除後の内分泌療法は推奨されるか？	("Carcinoma, Intraductal, Noninfiltrating/drug therapy"[MH] OR "Breast Carcinoma In Situ/drug therapy"[MH] OR "Carcinoma, Lobular/drug therapy"[MH] OR "Carcinoma, Intraductal, Noninfiltrating/drug therapy"[MH]) AND ("Neoadjuvant Therapy"[MH] OR "neoadjuvant"[TIAB] OR "preoperative"[TIAB]) AND (("Antineoplastic Agents, Hormonal"[MH] OR "Antineoplastic Agents, Hormonal" [PA]) OR ("Aromatase Inhibitors"[MH] OR "Aromatase Inhibitors" [PA]) OR "Tamoxifen"[MH] OR "Letrozole"[MH] OR "Anastrozole"[MH] OR "exemestane" [NM] OR ("Nitriles"[MH] OR ("Triazoles"[MH] AND ("2016"[DP] : "2018"[DP]))) AND (english[LA] OR japanese[LA]) AND ("2016/01"[DP] : "2021/03"[DP]))
CQ2	閉経前ホルモン受容体陽性乳癌に対する術後内分泌療法として何が推奨されるか？	((("Breast Neoplasms/drug therapy"[MH] AND ("Premenopause"[MH])) AND ("Chemotherapy, Adjuvant"[MH])) AND (((("Antineoplastic Agents, Hormonal"[MH] OR "Antineoplastic Agents, Hormonal" [PA]) OR ("Tamoxifen"[MH])) OR ("Gonadotropin-Releasing Hormone"[MH])) OR ("Receptors, Estrogen"[MH])) OR ("Aromatase Inhibitors"[MH] OR "Aromatase Inhibitors" [PA])) AND ((2016/1:2021/3[DP]) AND (english[LA] OR japanese[LA])) AND (Systematic Review[PT] OR systematic[SB] OR Meta-Analysis[PT]))
CQ3	閉経後ホルモン受容体陽性乳癌に対する術後内分泌療法として何が推奨されるか？	Breast Neoplasms/drug therapy[MH] AND (postmenopause[MH] OR postmenopausal*[TIAB] OR postmenopause*[TIAB]) AND "Chemotherapy, Adjuvant"[MH] AND (("Antineoplastic Agents, Hormonal"[MH] OR "Antineoplastic Agents, Hormonal" [PA]) OR "Tamoxifen"[MH] OR "Receptors, Estrogen"[MH] OR ("Estrogen Antagonists"[MH] OR "Estrogen Antagonists" [PA]) OR ("Aromatase Inhibitors"[MH] OR "Aromatase Inhibitors" [PA]) OR "Letrozole"[MH] OR "Anastrozole"[MH] OR "exemestane" [NM] OR ("Nitriles"[MH] OR ("Triazoles"[MH] AND ("2016"[DP] : "2018"[DP]))) AND (english[LA] OR japanese[LA]) AND ("2016/01"[DP] : "2021/03"[DP])) AND (Systematic Review[PT] OR systematic[SB] OR Meta-Analysis[PT]))

CQ4	浸潤性乳癌に対して、術後5年間の内分泌療法後に内分泌療法の追加投与は勧められるか？	("Breast Neoplasms/drug therapy"[MH] AND "Chemotherapy, Adjuvant"[MH] AND (("Antineoplastic Agents, Hormonal"[MH] OR "Antineoplastic Agents, Hormonal" [PA]) OR "Tamoxifen"[MH] OR "Gonadotropin-Releasing Hormone"[MH] OR ("Aromatase Inhibitors"[MH] OR "Aromatase Inhibitors" [PA]) OR ("Estrogen Antagonists"[MH] OR "Estrogen Antagonists" [PA]) OR "Receptors, Estrogen"[MH] OR "Letrozole"[MH] OR "Anastrozole"[MH] OR "exemestane" [NM] OR (("Nitriles"[MH] OR "Triazoles"[MH]) AND ("2016"[DP] : "2018"[DP]))) AND ("treatment duration"[TIAB] OR "treatment period"[TIAB] OR "administration period"[TIAB] OR "administration periods"[TIAB] OR "administration and dosage" [SH] OR "Drug Administration Schedule"[MH]) AND (english[LA] OR japanese[LA]) AND ("2016/01"[DP] : "2021/03"[DP])) AND (Systematic Review[PT] OR systematic[SB] OR Meta-Analysis[PT])
CQ5	ホルモン受容体陽性HER2陰性乳癌に対する術後療法として、内分泌療法にS-1を併用することは勧められるか？	(((Breast Neoplasms[MH] OR "breast cancer"[tiab]) AND (Receptor, ErbB-2[MH] OR "HER2"[Tiab]) AND (("endocrine therapy"[TIAB] OR "Hormone therapy"[TIAB] OR "Antineoplastic Combined Chemotherapy Protocols"[MH] OR Chemotherapy, Adjuvant[MH] OR "Antineoplastic Agents"[MH] OR tamoxifen[TW] OR Norvadex[TW] OR toremifene[TW] OR Fareston[TW] OR "Aromatase Inhibitors"[MH] OR "Aromatase Inhibitors" [PA] OR anastrozole[TW] OR Arimidex[TW] OR letrozole[TW] OR Femara[TW] OR exemestane [TW] OR Aromasin [TW] OR fulvestrant[TW] OR Faslodex[TW]) OR ("Cyclin-Dependent Kinase 4"[MH] OR "Cyclin-Dependent Kinase 6"[MH] OR "palbociclib"[TW] OR Ibrance [TW] OR abemaciclib[TW] OR Verzenio[TIAB] OR ribociclib[TW] OR LEE011[TW] OR Kisqali[TW] OR cdk[TW]) OR (everolimus[TW] OR afinitor[TW]) OR (P13K[TW] OR buparlisib[TW] OR "NVP-BKM120" [Supplementary Concept] OR pictilisib[TW] OR "2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine" [Supplementary Concept] OR "Alpelisib" [TW] OR PIQRAY[TW]) OR ("AKT inhibitor"[TW] OR "5233705 compound" [Supplementary Concept] OR "capivasertib" [TW] OR AZD5363[TW])) AND (Tegafur[MH] OR Oxonic Acid[MH] OR "S-1"[Tiab] OR "TS-1"[Tiab])) AND Human [MH] AND (English[LA] OR Japanese[LA]) AND (0001[DP] : 2021/3/31[DP]))
CQ6	ホルモン受容体陽性HER2陰性乳癌に対する術後療法として、内分泌療法にアベマシクリブを併用することは勧められるか？	(((Breast Neoplasms[MH] OR "breast cancer"[tiab]) AND (Receptor, ErbB-2[MH] OR "HER2"[Tiab]) AND (Receptors, Estrogen[MH] OR Receptors, Progesterone[MH] OR "Hormone receptor positive"[Tiab]) AND ("endocrine therapy"[TIAB] OR "Hormone therapy"[TIAB] OR "Antineoplastic Agents, Hormonal"[MH]) AND (abemaciclib[Tiab] OR Verzenio[Tiab] OR "Cyclin-Dependent Kinase 4"[MH] OR "Cyclin-Dependent Kinase 6"[MH] OR "palbociclib"[TW] OR Ibrance [TW] OR ribociclib[TW] OR LEE011[TW] OR Kisqali[TW] OR cdk[TW])) AND Human [MH] AND (English[LA] OR Japanese[LA]) AND (0001[DP] : 2021/3/31[DP]))
FRQ1	ホルモン受容体陽性HER2陰性浸潤性乳癌に対して術前内分泌療法は勧められるか？	(Breast neoplasms/drug therapy[MH]) AND ("Neoadjuvant Therapy"[MH] OR ("neoadjuvant"[TIAB] OR "preoperative"[TIAB])) AND (("Antineoplastic Agents, Hormonal"[MH] OR "Antineoplastic Agents, Hormonal" [PA]) OR ("Aromatase Inhibitors"[MH] OR "Aromatase Inhibitors" [PA]) OR "Tamoxifen"[MH] OR "Letrozole"[MH] OR "Anastrozole"[MH] OR "exemestane" [NM] OR(("Nitriles"[MH] OR "Triazoles"[MH]) AND ("2016"[DP] : "2018"[DP]))) AND (english[LA] OR japanese[LA]) AND ("2016/01"[DP] : "2021/03"[DP]) AND (Systematic Review[PT] OR systematic[SB] OR Meta-Analysis[PT])

FRQ2	浸潤径0.5cm以下でリンパ節転移陰性のホルモン受容体陽性乳癌に対して、術後内分泌療法省略は推奨されるか？	((((Breast neoplasms/therapy[MH]) AND ((Chemotherapy, Adjuvant[MH] OR ("Drug Therapy, Combination"[MH] AND 1974:1983[MHDA]) OR ("Combined Modality Therapy"[MH:NoExp] )) OR (adjuvant[Title/Abstract] OR postoperat*[Title/Abstract]))) AND (((((((("Antineoplastic Agents, Hormonal"[MH] OR ("Antineoplastic Agents"[MH:NoExp] AND 1966:1995[MHDA]) OR "Antineoplastic Agents, Hormonal" [PA]) OR ("Aromatase Inhibitors"[MH] OR "Aromatase Inhibitors" [PA])) OR ("Tamoxifen"[MH] OR ("Stilbenes"[MH:NoExp] AND 1966:1974[MHDA]) OR ("Phenyl Ethers"[MH] AND 1974[MHDA]) OR ("Dimethylamines"[MH] AND 1973:1974[MHDA]))) OR ("Letrozole"[MH]) OR ("Anastrozole"[MH]) OR ("exemestane" [NM])) OR (((("Nitriles"[MH] OR "Triazoles"[MH]) AND ("2016"[DP] : "2018"[DP]))) OR ((("Gonadotropin-Releasing Hormone"[MH] OR goserelin[TIAB] OR LHRH[TIAB] OR LH-RH[TIAB])) OR ("Estrogen Antagonists"[MH] OR (Estrogens[MH] AND 1966:1977[MHDA]))) OR ("Receptors, Estrogen"[MH] OR (Estrogens[MH] AND 1966:1976[MHDA]) OR ("Receptors, Drug" AND 1968:1976[MHDA]) OR ("Receptors, Cell Surface"[MH] AND 1973:1976[MHDA]))) AND (((small*[TIAB]) OR (T1a[TIAB])) OR (T1mi[TIAB] OR less[TIAB] OR microinvasi*[TIAB])) AND ((NO[TIAB]) OR (node negative[TIAB])) OR (T1N0[TIAB]))) AND ((english[LA] OR japanese[LA]) AND ("0000"[DP] : "2021/03"[DP])) AND ((Systematic Review[PT] OR systematic[SB] OR Meta-Analysis[PT]))
CQ7	化学療法を行うHER2陰性の早期乳癌に対して、アンスラサイクリンとタキサン順次投与は勧められるか？	(Breast Neoplasms[MH] OR "breast cancer"[TIAB]) AND (("Neoadjuvant Therapy"[Mesh] OR neoadjuvant[TIAB] OR preoperative[TW] OR "Chemotherapy, Adjuvant"[MH] OR adjuvant[TIAB]) AND ("Drug Therapy"[mesh:noexp] OR "Drug Therapy"[SH] OR "Combined Modality Therapy"[mesh:noexp])) AND (Anthracyclines[MH] OR anthracyclines[TIAB] OR doxorubicin[TIAB] OR epirubicin[TIAB] OR anthracyclines[TIAB]) AND (Taxoids[MH] OR taxoids[TIAB] OR paclitaxel[TIAB] OR docetaxel[TIAB] OR nab-paclitaxel[TIAB]) AND (Meta-Analysis[PT] OR Systematic[SB] OR randomized controlled trial[PT] OR Controlled Clinical Trial [PT]) AND ("1000/01/01"[PDAT] : "2021/03/31"[PDAT]) AND (English[lang] OR Japanese[lang])
CQ8	化学療法を行うHER2陰性の早期乳癌に対して、TC療法は勧められるか？	(Breast Neoplasms[MH] OR "breast cancer"[TIAB]) AND (("Neoadjuvant Therapy"[Mesh] OR neoadjuvant[TIAB] OR preoperative[TW] OR "Chemotherapy, Adjuvant"[MH] OR adjuvant[TIAB] OR Antineoplastic Combined Chemotherapy Protocols[MH]) AND ("Drug Therapy"[mesh:noexp] OR "Drug Therapy"[SH] OR "Combined Modality Therapy"[mesh:noexp])) AND ((Docetaxel[MH] OR docetaxel[TIAB]) AND (Cyclophosphamide[MH] OR cyclophosphamide[TIAB])) AND (randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR clinical trials as topic[mesh:noexp] OR randomly[tiab] OR trial[ti] NOT (animals[mh] NOT humans [mh])) AND ("1000/01/01"[PDAT] : "2021/03/31"[PDAT]) AND (English[lang] OR Japanese[lang])
CQ9	化学療法を行う早期乳癌に対して、dose—dense化学療法は勧められるか？	(Breast Neoplasms[MH] OR "breast cancer"[TIAB]) AND ("dose dense"[TIAB] OR "short interval"[TIAB]) AND (randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR clinical trials as topic[mesh:noexp] OR randomly[tiab] OR trial[ti] NOT (animals[mh] NOT humans [mh])) AND ("1000/01/01"[PDAT] : "2021/03/31"[PDAT]) AND (English[lang] OR Japanese[lang])

CQ10	術前化学療法で病理的完全奏効（pCR）を得られなかったHER2陰性早期乳癌に対する術後化学療法として、カペシタピンは勧められるか？	(Breast Neoplasms[MH] OR "breast cancer"[TIAB]) AND (("Neoadjuvant Therapy"[Mesh] OR neoadjuvant[TIAB] OR preoperative[TW] OR "Chemotherapy, Adjuvant"[MH] OR adjuvant[TIAB]) AND ("Drug Therapy"[mesh:noexp] OR "Drug Therapy"[SH] OR "Combined Modality Therapy"[mesh:noexp])) AND (Capecitabine[MH] OR capecitabine[TIAB] OR "Ro 09-1978"[TIAB] OR Ro-09-1978[TIAB] OR Ro09-1978[TIAB] OR Xeloda[TIAB]) AND (Meta-Analysis[PT] OR Systematic[SB] OR randomized controlled trial[PT] OR Controlled Clinical Trial [PT]) AND ("1000/01/01"[PDAT] : "2021/03/31"[PDAT]) AND (English[lang] OR Japanese[lang])
CQ11	ホルモン受容体陽性HER2陰性乳癌に対して、多遺伝子アッセイの結果によって、術後化学療法を省略することは推奨されるか？	(Breast Neoplasms[MH] OR "breast cancer"[TIAB]) AND (Gene Expression Profiling[MH] OR Transcriptome[MH] OR transcriptome*[TW] OR "Gene Expression Signature"[TIAB] OR "gene assay"[TIAB] OR 21-gene[TIAB] OR 70-gene[TIAB] OR 95-gene[TIAB] OR PAM50[TIAB] OR "Oncotype DX"[TIAB] OR Curebest[TIAB] OR MammaPrint[TIAB]) AND ((randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR clinical trials as topic[mesh:noexp] OR randomly[tiab] OR trial[ti] NOT (animals[mh] NOT humans [mh])) AND ("2020/01/01"[PDAT] : "2021/03/31"[PDAT]) AND (English[lang] OR Japanese[lang]))
CQ12	術前薬物療法を行うHER2陽性早期乳癌に対して、トラスツズマブにペルツズマブを加えることは勧められるか？	(Breast Neoplasms[MH] OR "breast cancer"[TIAB]) AND (("Neoadjuvant Therapy"[Mesh] OR neoadjuvant[TIAB]) AND ("Drug Therapy"[mesh:noexp] OR "Drug Therapy"[SH] OR "Combined Modality Therapy"[mesh:noexp])) AND (Trastuzumab[MH] OR Trastuzumab[TIAB] OR Herceptin[TIAB] OR "MKC 454"[TIAB] OR MKC-454[TIAB] OR Tmab[TIAB]) AND (Pertuzumab[NM] OR Pertuzumab[TIAB] OR Omnitarg[TIAB] OR Perjeta[TIAB] OR RO4368451[TIAB]) AND (Meta-Analysis[PT] OR Systematic[SB] OR randomized controlled trial[PT] OR Controlled Clinical Trial [PT]) AND ("2016/01/01"[PDAT] : "2021/03/31"[PDAT]) AND (English[lang] OR Japanese[lang])
CQ13	術前薬物療法で病理的完全奏効（pCR）を得られなかったHER2陽性早期乳癌に対する術後薬物療法として、トラスツズマブ エムタンシンは勧められるか？	(Breast Neoplasms[MH] OR "breast cancer"[TIAB]) AND (("Neoadjuvant Therapy"[Mesh] OR neoadjuvant[TIAB] OR preoperative[TW] OR "Chemotherapy, Adjuvant"[MH] OR adjuvant[TIAB]) AND ("Drug Therapy"[mesh:noexp] OR "Drug Therapy"[SH] OR "Combined Modality Therapy"[mesh:noexp])) AND (Ado-Trastuzumab Emtansine[MH] OR "Trastuzumab Emtansine"[TIAB] OR T-DM1[TIAB] OR TDM1[TIAB] OR "response guide*" [TIAB] OR "Kadcyla"[TIAB]) AND (Meta-Analysis[PT] OR Systematic[SB] OR randomized controlled trial[PT] OR Controlled Clinical Trial [PT]) AND ("1000/01/01"[PDAT] : "2021/03/31"[PDAT]) AND (English[lang] OR Japanese[lang])
CQ14	術後薬物療法を行うHER2陽性早期乳癌に対して、トラスツズマブにペルツズマブを加えることは勧められるか？	(Breast Neoplasms[MH] OR "breast cancer"[TIAB]) AND (("Chemotherapy, Adjuvant"[MH] OR adjuvant[TIAB]) AND ("Drug Therapy"[mesh:noexp] OR "Drug Therapy"[SH] OR "Combined Modality Therapy"[mesh:noexp])) AND (Trastuzumab[MH] OR Trastuzumab[TIAB] OR Herceptin[TIAB] OR "MKC 454"[TIAB] OR MKC-454[TIAB] OR Tmab[TIAB]) AND (Pertuzumab[NM] OR Pertuzumab[TIAB] OR Omnitarg[TIAB] OR Perjeta[TIAB] OR RO4368451[TIAB]) AND (randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR clinical trials as topic[mesh:noexp] OR randomly[tiab] OR trial[ti] NOT (animals[mh] NOT humans [mh])) AND ("2016/01/01"[PDAT] : "2021/03/31"[PDAT]) AND (English[lang] OR Japanese[lang])

FRQ3	HER2陽性早期乳癌に対する術後薬物療法として、アンストラサイクリンを省略したタキサンとトラスツズマブによる併用療法は勧められるか？	(Breast Neoplasms[MH] OR "breast cancer"[TIAB]) AND ("Chemotherapy, Adjuvant"[MH] OR adjuvant[TIAB]) AND (Trastuzumab[MH] OR Trastuzumab[TIAB] OR Herceptin[TIAB] OR "MKC 454"[TIAB] OR MKC-454[TIAB] OR Tmab[TIAB]) AND (Taxoids[MH] OR taxane[TIAB] OR Paclitaxel[MH] OR paclitaxel[TIAB] OR 7epiTaxol[TIAB] OR "BMS 181339"[TIAB] OR BMS-181339[TIAB] OR BMS181339[TIAB] OR Genexol[TIAB] OR "NSC 125973"[TIAB] OR NSC125973[TIAB] OR OncoGel[TIAB] OR "PAC (Paclitaxel)"[TIAB] OR "PTX (Paclitaxel)"[TIAB]) AND (randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR clinical trials as topic[mesh:noexp] OR randomly[tiab] OR trial[ti] OR Multicenter Study[PT] OR Clinical Trial, Phase II[PT] OR Comparative Study[PT] NOT (animals[mh] NOT humans [mh])) AND ("1000/01/01"[PDAT] : "2021/03/31"[PDAT]) AND (English[lang] OR Japanese[lang])
CQ15	高齢者のHER2陽性早期乳癌に対する術後薬物療法として、トラスツズマブのみによる治療は勧められるか？	(Breast Neoplasms[MH] OR "breast cancer"[TIAB]) AND (("Chemotherapy, Adjuvant"[MH] OR adjuvant[TIAB]) AND ("Drug Therapy"[mesh:noexp] OR "Drug Therapy"[SH] OR "Combined Modality Therapy"[mesh:noexp])) AND (Trastuzumab[MH] OR Trastuzumab[TIAB] OR Herceptin[TIAB] OR "MKC 454"[TIAB] OR MKC-454[TIAB] OR Tmab[TIAB]) AND (Aged[MH] or aged[TIAB] or elderly[TIAB]) AND (randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR clinical trials as topic[mesh:noexp] OR randomly[tiab] OR trial[ti] NOT (animals[mh] NOT humans [mh])) AND ("1000/01/01"[PDAT] : "2021/03/31"[PDAT]) AND (English[lang] OR Japanese[lang])
CQ16	周術期トリプルネガティブ乳癌に対して、免疫チェックポイント阻害薬は勧められるか？	("breast neoplasms"[MeSH Terms] OR "breast cancer"[Title/Abstract]) AND "triple-negative"[Title/Abstract] AND ("Immune Checkpoint Inhibitors"[MeSH Terms] OR "Immune Checkpoint Inhibitors"[Pharmacological Action] OR "checkpoint"[Text Word] OR "atezolizumab"[Text Word] OR "pembrolizumab"[Text Word]) AND (("Combined Modality Therapy"[MeSH Terms:noexp] AND "chemotherapy, adjuvant"[MeSH Terms]) OR "Neoadjuvant Therapy"[MeSH Terms] OR "surgery"[MeSH Subheading] OR ("adjuvant"[Title/Abstract] OR "neoadjuvant"[Title/Abstract])) AND ("English"[Language] OR "Japanese"[Language]) AND 0001/01/01:2021/03/31[Date - Publication]

CQ17	トリプルネガティブ早期乳癌に対して、プラチナ製剤は勧められるか？	(("Breast Neoplasms"[MeSH Terms] OR "breast cancer"[Title/Abstract]) AND "triple negative"[Text Word] AND ("adjuvant"[Text Word] OR "neoadjuvant"[Text Word] OR "Combined Modality Therapy"[MeSH Terms] OR "antineoplastic combined chemotherapy protocols"[MeSH Terms] OR ("postoperative"[Text Word] OR "perioperative"[Text Word] OR "preoperative"[Text Word])) AND ("Platinum Compounds"[MeSH Terms] OR ("platinum"[Text Word] OR "carboplatin"[Text Word] OR "cisplatin"[Text Word])) AND 0001/01/01:2021/03/31[Date - Publication] AND ("English"[Language] OR "Japanese"[Language]) AND (("randomized controlled trial"[Publication Type] OR "controlled clinical trial"[Publication Type] OR "randomized"[Title/Abstract] OR "placebo"[Title/Abstract] OR "clinical trials as topic"[MeSH Terms:noexp] OR "randomly"[Title/Abstract] OR "trial"[Title]) NOT ("animals"[MeSH Terms] NOT "humans"[MeSH Terms]))) OR (("Breast Neoplasms"[MeSH Terms] OR "breast cancer"[Title/Abstract]) AND "triple negative"[Text Word] AND ("adjuvant"[Text Word] OR "neoadjuvant"[Text Word] OR "Combined Modality Therapy"[MeSH Terms] OR "antineoplastic combined chemotherapy protocols"[MeSH Terms] OR ("postoperative"[Text Word] OR "perioperative"[Text Word] OR "preoperative"[Text Word])) AND ("Platinum Compounds"[MeSH Terms] OR ("platinum"[Text Word] OR "carboplatin"[Text Word] OR "cisplatin"[Text Word])) AND 0001/01/01:2021/03/31[Date - Publication] AND ("English"[Language] OR "Japanese"[Language]) AND ("Systematic"[Filter] OR "Meta-Analysis"[Publication Type]))
FRQ4	浸潤径1cm以下・リンパ節転移陰性のトリプルネガティブ乳癌に対して、術後化学療法は勧められるか？	(((Triple Negative Breast Neoplasms[MH] OR ("triple negative"[TIAB] AND "breast cancer*"[TIAB])) AND ("Chemotherapy, Adjuvant"[MH] OR adjuvant[TIAB])) OR ((Breast Neoplasms[MH] OR "breast cancer"[TIAB]) AND adjuvant[TIAB] AND (T1ab[TIAB] or 1cm[TIAB] or pT1ab[TIAB]))) AND (randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR clinical trials as topic[mesh:noexp] OR randomly[tiab] OR trial[ti] OR Multicenter Study[PT] NOT (animals[mh] NOT humans [mh])) AND ("1000/01/01"[PDAT] : "2021/03/31"[PDAT]) AND (English[lang] OR Japanese[lang])
FRQ5	BRCA病的バリエントを有する乳癌患者の周術期薬物療法として何が勧められるか？	(("Breast Neoplasms/drug therapy"[MH]) AND (("BRCA1 Protein"[MH] OR "Genes, BRCA1"[MH] OR "BRCA1 protein, human" [NM]) OR ("Genes, BRCA2"[MH] OR "BRCA2 Protein"[MH] OR "BRCA2 protein, human" [NM] ))) AND (((("Chemotherapy, Adjuvant"[MH]) OR "Neoadjuvant Therapy"[MH]) OR (adjuvant[TIAB] OR neoadjuvant[TIAB] OR postoperat*[TIAB] OR preoperat*[TIAB] OR perioperat*[TIAB])) AND (english[LA] OR japanese[LA]) AND ("0000"[DP] : "2021/03"[DP]) AND (Systematic Review[PT] OR systematic[SB] OR Meta-Analysis[PT])

FRQ6	早期男性乳癌に対する薬物療法は何が推奨されるか？	((((("Breast Neoplasms, Male/drug therapy"[MH]) OR (("Breast Neoplasms/drug therapy"[MH:NoExp] AND 0000[DP]:1994[DP]) AND ("Male"[MH]))) OR ("male breast cancer"[TIAB])) AND (((("Neoadjuvant Therapy"[MH]) OR "Chemotherapy, Adjuvant"[MH]) OR (adjuvant[TIAB] OR neoadjuvant[TIAB] OR postoperat*[TIAB] OR preoperat*[TIAB] OR perioperat*[TIAB]))) AND (((((((("Antineoplastic Agents" [PA] OR "Antineoplastic Agents, Hormonal" [PA] OR "Antineoplastic Agents"[MH]) OR ("Aromatase Inhibitors"[MH] OR "Aromatase Inhibitors" [PA])) OR ("Tamoxifen"[MH] OR ("Stilbenes"[MH:NoExp] AND 1966:1974[MHDA]) OR ("Phenyl Ethers"[MH] AND 1974[MHDA]) OR ("Dimethylamines"[MH] AND 1973:1974[MHDA]) OR tamoxifen[TIAB])) OR ("Letrozole"[MH] OR letrozole[TIAB])) OR ("Anastrozole"[MH] OR anastrozole[TIAB])) OR ("exemestane" [NM] OR exemestane[TIAB])) OR (((("Nitriles"[MH]) OR "Triazoles"[MH]) AND ("2016"[DP] : "2018"[DP]))) OR ("palbociclib" [NM] OR palbociclib[TIAB])) AND (english[LA] OR japanese[LA]) AND ("0000"[DP] : "2021/03"[DP]) AND (Systematic Review[PT] OR systematic[SB] OR Meta-Analysis[PT])
FRQ7	早期高齢者乳癌患者に対して周術期の化学療法は勧められるか？	breast neoplasms/drug therapy[MeSH Terms] AND ("Aged"[MeSH Terms] OR ("elderly"[Title/Abstract] OR "older*" [Title/Abstract])) AND ("Antineoplastic Agents"[MeSH Terms:noexp] OR "Antineoplastic Agents"[Pharmacological Action] OR "antineoplastic agents, hormonal"[MeSH Terms] OR "chemotherapy, adjuvant"[MeSH Terms:noexp] OR "Neoadjuvant Therapy"[MeSH Terms] OR "Adjuvant"[Title/Abstract] OR "antineoplastic combined chemotherapy protocols"[MeSH Terms]) AND 2016/01/01:2021/03/31[Date - Publication] AND ("English"[Language] OR "Japanese"[Language]) AND "Randomized Controlled Trial"[Publication Type]
FRQ9	原発乳癌に対する再発予防を目的とする術後薬物療法として骨吸収抑制薬（ビスホスホネート製剤，デノスマブ）は勧められるか？	"breast neoplasms"[MeSH Terms] AND ("Diphosphonates"[MeSH Terms] OR "bisphosphonate*" [Title/Abstract] OR "Denosumab"[MeSH Terms] OR ("Bone Density Conservation Agents"[MeSH Terms] OR "Bone Density Conservation Agents"[Pharmacological Action])) AND "early"[Title/Abstract] AND "adjuvant"[Text Word] AND ("English"[Language] OR "Japanese"[Language]) AND 0001/01/01:2021/03/31[Date - Publication] AND "randomized controlled trial"[Publication Type]
BQ5	閉経前ホルモン受容体陽性転移・再発乳癌に対して最も有用な卵巣機能抑制方法は何か？	(((Breast Neoplasms[MH]) AND (Premenopause[MH] OR Premenopausal [Tiab]) AND ((Ovariectomy[MH] OR "ovarian ablation"[Tiab]) OR (Leuprolide[MH] OR Goserelin[MH] OR triptorelin[MH]))) AND "Humans"[MH] AND ("2016/01/01"[DP] : "2021/3/31"[DP]) AND ("English"[LA] OR "Japanese"[LA]))

CQ18	閉経前ホルモン受容体陽性 HER2陰性転移・再発乳癌に対する一次内分泌療法として、何が推奨されるか？	(((Breast Neoplasms[MH] OR "breast cancer"[tiab]) AND (advanced[TIAB] OR metastatic[TIAB] OR "Neoplasm Metastasis"[MH] OR "Neoplasm Recurrence, Local"[MH]) AND ("endocrine therapy"[TIAB] OR "Hormone therapy"[TIAB] OR "Antineoplastic Combined Chemotherapy Protocols"[MH] OR "Antineoplastic Agents, Hormonal"[MH] OR tamoxifen[TW] OR Norvadex[TW] OR toremifene[TW] OR Fareston[TW] OR "Aromatase Inhibitors"[MH] OR "Aromatase Inhibitors" [PA] OR anastrozole[TW] OR Arimidex[TW] OR letrozole[TW] OR Femara[TW] OR exemestane [TW] OR Aromasin [TW] OR fulvestrant[TW] OR Faslodex[TW] OR MONARCH[Tiab]) AND (("Cyclin-Dependent Kinase 4"[MH] OR "Cyclin-Dependent Kinase 6"[MH] OR "palbociclib"[TW] OR Ibrance [TW] OR abemaciclib[TW] OR Verzenio[TIAB] OR ribociclib[TW] OR LEE011[TW] OR KISQALI[TW] OR cdk[TW]) OR (everolimus[TW] OR afinitor[TW]) OR (P13K[TW] OR buparlisib[TW] OR "NVP-BKM120" [Supplementary Concept] OR pictilisib[TW] OR "2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine" [Supplementary Concept] OR "Alpelisib" [TW] OR PIQRAY[TW]) OR ("AKT inhibitor"[TW] OR "5233705 compound" [Supplementary Concept] OR "capivasertib" [TW] OR AZD5363[TW]))) AND (English[LA] OR Japanese[LA]) AND (2016/1/1[DP] : 2021/3/31[DP]))
CQ19	閉経前ホルモン受容体陽性 HER2陰性転移・再発乳癌に対する二次以降の内分泌療法として、何が推奨されるか？	(((Breast Neoplasms[MH] OR "breast cancer"[tiab]) AND (advanced[TIAB] OR metastatic[TIAB] OR "Neoplasm Metastasis"[MH] OR "Neoplasm Recurrence, Local"[MH]) AND ("endocrine therapy"[TIAB] OR "Hormone therapy"[TIAB] OR "Antineoplastic Combined Chemotherapy Protocols"[MH] OR "Antineoplastic Agents, Hormonal"[MH] OR tamoxifen[TW] OR Norvadex[TW] OR toremifene[TW] OR Fareston[TW] OR "Aromatase Inhibitors"[MH] OR "Aromatase Inhibitors" [PA] OR anastrozole[TW] OR Arimidex[TW] OR letrozole[TW] OR Femara[TW] OR exemestane [TW] OR Aromasin [TW] OR fulvestrant[TW] OR Faslodex[TW] OR MONARCH[Tiab]) AND (("Cyclin-Dependent Kinase 4"[MH] OR "Cyclin-Dependent Kinase 6"[MH] OR "palbociclib"[TW] OR Ibrance [TW] OR abemaciclib[TW] OR Verzenio[TIAB] OR ribociclib[TW] OR LEE011[TW] OR KISQALI[TW] OR cdk[TW]) OR (everolimus[TW] OR afinitor[TW]) OR (P13K[TW] OR buparlisib[TW] OR "NVP-BKM120" [Supplementary Concept] OR pictilisib[TW] OR "2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine" [Supplementary Concept] OR "Alpelisib" [TW] OR PIQRAY[TW]) OR ("AKT inhibitor"[TW] OR "5233705 compound" [Supplementary Concept] OR "capivasertib" [TW] OR AZD5363[TW]))) AND (English[LA] OR Japanese[LA]) AND (2016/1/1[DP] : 2021/3/31[DP]))



CQ20	閉経後ホルモン受容体陽性 HER2陰性転移・再発乳癌に対する一次内分泌療法として、何が推奨されるか？	(((Breast Neoplasms[MH] OR "breast cancer"[tiab]) AND (advanced[TIAB] OR metastatic[TIAB] OR "Neoplasm Metastasis"[MH] OR "Neoplasm Recurrence, Local"[MH]) AND ("endocrine therapy"[TIAB] OR "Hormone therapy"[TIAB] OR "Antineoplastic Combined Chemotherapy Protocols"[MH] OR "Antineoplastic Agents, Hormonal"[MH] OR tamoxifen[TW] OR Norvadex[TW] OR toremifene[TW] OR Fareston[TW] OR "Aromatase Inhibitors"[MH] OR "Aromatase Inhibitors" [PA] OR anastrozole[TW] OR Arimidex[TW] OR letrozole[TW] OR Femara[TW] OR exemestane [TW] OR Aromasin [TW] OR fulvestrant[TW] OR Faslodex[TW] OR MONARCH[Tiab]) AND (("Cyclin-Dependent Kinase 4"[MH] OR "Cyclin-Dependent Kinase 6"[MH] OR "palbociclib"[TW] OR Ibrance [TW] OR abemaciclib[TW] OR Verzenio[TIAB] OR ribociclib[TW] OR LEE011[TW] OR KISQALI[TW] OR cdk[TW]) OR (everolimus[TW] OR afinitor[TW]) OR (P13K[TW] OR buparlisib[TW] OR "NVP-BKM120" [Supplementary Concept] OR pictilisib[TW] OR "2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine" [Supplementary Concept] OR "Alpelisib" [TW] OR PIQRAY[TW]) OR ("AKT inhibitor"[TW] OR "5233705 compound" [Supplementary Concept] OR "capivasertib" [TW] OR AZD5363[TW]))) AND (English[LA] OR Japanese[LA]) AND (2016/1/1[DP] : 2021/3/31[DP]))
CQ21	閉経後ホルモン受容体陽性 HER2陰性転移・再発乳癌に対する一次内分泌療法にアロマターゼ阻害薬単剤を使用したときの二次内分泌療法として、何が推奨されるか？	(((Breast Neoplasms[MH] OR "breast cancer"[tiab]) AND (advanced[TIAB] OR metastatic[TIAB] OR "Neoplasm Metastasis"[MH] OR "Neoplasm Recurrence, Local"[MH]) AND ("endocrine therapy"[TIAB] OR "Hormone therapy"[TIAB] OR "Antineoplastic Combined Chemotherapy Protocols"[MH] OR "Antineoplastic Agents, Hormonal"[MH] OR tamoxifen[TW] OR Norvadex[TW] OR toremifene[TW] OR Fareston[TW] OR "Aromatase Inhibitors"[MH] OR "Aromatase Inhibitors" [PA] OR anastrozole[TW] OR Arimidex[TW] OR letrozole[TW] OR Femara[TW] OR exemestane [TW] OR Aromasin [TW] OR fulvestrant[TW] OR Faslodex[TW] OR MONARCH[Tiab]) AND (("Cyclin-Dependent Kinase 4"[MH] OR "Cyclin-Dependent Kinase 6"[MH] OR "palbociclib"[TW] OR Ibrance [TW] OR abemaciclib[TW] OR Verzenio[TIAB] OR ribociclib[TW] OR LEE011[TW] OR KISQALI[TW] OR cdk[TW]) OR (everolimus[TW] OR afinitor[TW]) OR (P13K[TW] OR buparlisib[TW] OR "NVP-BKM120" [Supplementary Concept] OR pictilisib[TW] OR "2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine" [Supplementary Concept] OR "Alpelisib" [TW] OR PIQRAY[TW]) OR ("AKT inhibitor"[TW] OR "5233705 compound" [Supplementary Concept] OR "capivasertib" [TW] OR AZD5363[TW]))) AND (English[LA] OR Japanese[LA]) AND (2016/1/1[DP] : 2021/3/31[DP]))

FRQ10	閉経後ホルモン受容体陽性 HER2陰性転移・再発乳癌の二次内分泌療法として、何が推奨されるか？	(((Breast Neoplasms[MH] OR "breast cancer"[tiab]) AND (advanced[TIAB] OR metastatic[TIAB] OR "Neoplasm Metastasis"[MH] OR "Neoplasm Recurrence, Local"[MH]) AND ("endocrine therapy"[TIAB] OR "Hormone therapy"[TIAB] OR "Antineoplastic Combined Chemotherapy Protocols"[MH] OR "Antineoplastic Agents, Hormonal"[MH] OR tamoxifen[TW] OR Norvadex[TW] OR toremifene[TW] OR Fareston[TW] OR "Aromatase Inhibitors"[MH] OR "Aromatase Inhibitors" [PA] OR anastrozole[TW] OR Arimidex[TW] OR letrozole[TW] OR Femara[TW] OR exemestane [TW] OR Aromasin [TW] OR fulvestrant[TW] OR Faslodex[TW] OR MONARCH[Tiab]) AND (("Cyclin-Dependent Kinase 4"[MH] OR "Cyclin-Dependent Kinase 6"[MH] OR "palbociclib"[TW] OR Ibrance [TW] OR abemaciclib[TW] OR Verzenio[TIAB] OR ribociclib[TW] OR LEE011[TW] OR KISQALI[TW] OR cdk[TW]) OR (everolimus[TW] OR afinitor[TW]) OR (P13K[TW] OR buparlisib[TW] OR "NVP-BKM120" [Supplementary Concept] OR pictilisib[TW] OR "2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine" [Supplementary Concept] OR "Alpelisib" [TW] OR PIQRAY[TW] OR ("AKT inhibitor"[TW] OR "5233705 compound" [Supplementary Concept] OR "capivasertib" [TW] OR AZD5363[TW]))) AND (English[LA] OR Japanese[LA]) AND (2016/1/1[DP] : 2021/3/31[DP]))
FRQ11	PIK3CA遺伝子変異陽性ホルモン受容体陽性HER2陰性転移・再発乳癌に対して、PI3K阻害薬は有用か？	(((Breast Neoplasms[MH] OR "breast cancer"[Tiab]) AND (Receptors, Estrogen [MH] OR Estrogen Receptor positive[Tiab] OR ER+[TIAB] OR "ER positive"[TIAB]) AND (Class I Phosphatidylinositol 3-Kinases[MH] OR PIK3CA[Tiab]) AND ((Phosphoinositide-3 Kinase Inhibitors[MH] OR Phosphoinositide-3 Kinase[Tiab]) OR (Buparlisib[Tiab] OR Buparlisib[NM]) OR (alpelisib[Tiab] OR alpelisib[NM]) OR (Ipatasertib[Tiab] OR Ipatasertib[NM]) OR (taselisib[Tiab] OR taselisib[NM]) OR (Pictilisib[Tiab] OR Pictilisib[NM]))) AND (English[LA] OR Japanese[LA]) AND (0001[DP] : 2021/3/31[DP]))
CQ22	閉経後ホルモン受容体陽性 HER2陰性転移・再発乳癌に対する三次以降の内分泌療法として、何が推奨されるか？	(((Breast Neoplasms[MH] OR "breast cancer"[tiab]) AND (advanced[TIAB] OR metastatic[TIAB] OR "Neoplasm Metastasis"[MH] OR "Neoplasm Recurrence, Local"[MH]) AND ("endocrine therapy"[TIAB] OR "Hormone therapy"[TIAB] OR "Antineoplastic Combined Chemotherapy Protocols"[MH] OR "Antineoplastic Agents, Hormonal"[MH] OR tamoxifen[TW] OR Norvadex[TW] OR toremifene[TW] OR Fareston[TW] OR "Aromatase Inhibitors"[MH] OR "Aromatase Inhibitors" [PA] OR anastrozole[TW] OR Arimidex[TW] OR letrozole[TW] OR Femara[TW] OR exemestane [TW] OR Aromasin [TW] OR fulvestrant[TW] OR Faslodex[TW] OR MONARCH[Tiab]) AND (("Cyclin-Dependent Kinase 4"[MH] OR "Cyclin-Dependent Kinase 6"[MH] OR "palbociclib"[TW] OR Ibrance [TW] OR abemaciclib[TW] OR Verzenio[TIAB] OR ribociclib[TW] OR LEE011[TW] OR KISQALI[TW] OR cdk[TW]) OR (everolimus[TW] OR afinitor[TW]) OR (P13K[TW] OR buparlisib[TW] OR "NVP-BKM120" [Supplementary Concept] OR pictilisib[TW] OR "2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine" [Supplementary Concept] OR "Alpelisib" [TW] OR PIQRAY[TW] OR ("AKT inhibitor"[TW] OR "5233705 compound" [Supplementary Concept] OR "capivasertib" [TW] OR AZD5363[TW]))) AND (English[LA] OR Japanese[LA]) AND (2016/1/1[DP] : 2021/3/31[DP]))

BQ6	HER2陰性転移・再発乳癌に対する一次・二次化学療法として、アンストラサイクリン系薬剤は推奨されるか？	("breast neoplasms/secondary"[MeSH Terms] OR "Neoplasm Metastasis"[MeSH Terms] OR "neoplasm recurrence, local"[MeSH Terms] OR "metasta*"[Title/Abstract] OR "advanced"[Title/Abstract] OR "reccurren*"[Title/Abstract]) AND ("Doxorubicin"[Text Word] OR "Anthracyclines"[MeSH Terms]) AND "breast neoplasms/drug therapy"[MeSH Major Topic] AND 0001/01/01:2021/03/31[Date - Publication] AND ("English"[Language] OR "Japanese"[Language]) AND ("Randomized Controlled Trial"[Publication Type] OR "systematic"[Filter] OR "Meta-Analysis"[Publication Type])
CQ23	HER2陰性転移・再発乳癌に対する一次・二次化学療法としてベバシズマブを併用することは推奨されるか？	(("Breast Neoplasms"[MeSH Terms] OR "breast cancer"[Title/Abstract]) AND "Bevacizumab"[Text Word] AND ("advanced"[Title/Abstract] OR "metastatic"[Title/Abstract] OR "recurren*"[Title/Abstract] OR "Neoplasm Metastasis"[MeSH Terms] OR "neoplasm recurrence, local"[MeSH Terms]) AND ("English"[Language] OR "Japanese"[Language]) AND 2016/01/01:2021/03/31[Date - Publication] AND (("randomized controlled trial"[Publication Type] OR "controlled clinical trial"[Publication Type] OR "randomized"[Title/Abstract] OR "placebo"[Title/Abstract] OR "clinical trials as topic"[MeSH Terms:noexp] OR "randomly"[Title/Abstract] OR "trial"[Title]) NOT ("animals"[MeSH Terms] NOT "humans"[MeSH Terms]))) OR (("Breast Neoplasms"[MeSH Terms] OR "breast cancer"[Title/Abstract]) AND "Bevacizumab"[Text Word] AND ("advanced"[Title/Abstract] OR "metastatic"[Title/Abstract] OR "recurren*"[Title/Abstract] OR "Neoplasm Metastasis"[MeSH Terms] OR "neoplasm recurrence, local"[MeSH Terms]) AND ("English"[Language] OR "Japanese"[Language]) AND 2016/01/01:2021/03/31[Date - Publication] AND ("systematic"[Filter] OR "Meta-Analysis"[Publication Type]))
CQ24	HER2陰性転移・再発乳癌に対する一次・二次化学療法として経口フッ化ピリミジンは推奨されるか？	"breast neoplasms/drug therapy"[MeSH Terms] AND ("advanced"[Title/Abstract] OR "metastatic"[Title/Abstract] OR "recurren*"[Title/Abstract] OR "Neoplasm Metastasis"[MeSH Terms] OR "neoplasm recurrence, local"[MeSH Terms]) AND "fluorouracil"[MeSH Terms] AND ("first"[Title/Abstract] OR "second"[Title/Abstract]) AND ("English"[Language] OR "Japanese"[Language]) AND 0001/01/01:2021/03/31[Date - Publication] AND "randomized controlled trial"[Publication Type]
CQ25	HER2陰性転移・再発乳癌に対する一次・二次化学療法としてエリブリンは推奨されるか？	(("Breast Neoplasms"[MeSH Terms] OR "breast cancer"[Title/Abstract]) AND "eribulin"[Text Word] AND ("advanced"[Title/Abstract] OR "metastatic"[Title/Abstract] OR "recurren*"[Title/Abstract] OR "Neoplasm Metastasis"[MeSH Terms] OR "neoplasm recurrence, local"[MeSH Terms]) AND ("English"[Language] OR "Japanese"[Language]) AND 0001/01/01:2021/03/31[Date - Publication] AND ("systematic"[Filter] OR "Meta-Analysis"[Publication Type])) OR (("Breast Neoplasms"[MeSH Terms] OR "breast cancer"[Title/Abstract]) AND "eribulin"[Text Word] AND ("advanced"[Title/Abstract] OR "metastatic"[Title/Abstract] OR "recurren*"[Title/Abstract] OR "Neoplasm Metastasis"[MeSH Terms] OR "neoplasm recurrence, local"[MeSH Terms]) AND ("English"[Language] OR "Japanese"[Language]) AND 0001/01/01:2021/03/31[Date - Publication] AND (("randomized controlled trial"[Publication Type] OR "controlled clinical trial"[Publication Type] OR "randomized"[Title/Abstract] OR "placebo"[Title/Abstract] OR "clinical trials as topic"[MeSH Terms:noexp] OR "randomly"[Title/Abstract] OR "trial"[Title]) NOT ("animals"[MeSH Terms] NOT "humans"[MeSH Terms])))

<p>CQ26-28</p>	<p>CQ26：HER2陽性転移・再発乳癌に対する一次治療として、トラスツズマブ+ペルツズマブ+タキサン併用療法は推奨されるか？  CQ27：HER2陽性転移・再発乳癌に対する一次治療として、トラスツズマブ エムタンシンは推奨されるか？  CQ28：HER2陽性転移・再発乳癌に対する二次治療として、トラスツズマブ デルクステカンは推奨されるか？</p>	<p>((("Breast Neoplasms"[MeSH Terms] OR "breast cancer"[Title/Abstract]) AND ("breast neoplasms/secondary"[MeSH Terms] OR "Neoplasm Metastasis"[MeSH Terms] OR "neoplasm recurrence, local"[MeSH Terms] OR "metast*"[Title/Abstract] OR "advanced"[Title/Abstract] OR "reccurren*"[Title/Abstract]) AND ("Ado-Trastuzumab Emtansine"[MeSH Terms] OR "Trastuzumab Emtansine"[Title/Abstract] OR ("Trastuzumab"[MeSH Terms] AND "pertuzumab"[Supplementary Concept] AND ("Taxoids"[MeSH Terms] OR "taxoid*"[Title/Abstract] OR "taxane*"[Title/Abstract]))) AND ("English"[Language] OR "Japanese"[Language]) AND ((("randomized controlled trial"[Publication Type] OR "controlled clinical trial"[Publication Type] OR "randomized"[Title/Abstract] OR "placebo"[Title/Abstract] OR "clinical trials as topic"[MeSH Terms:noexp] OR "randomly"[Title/Abstract] OR "trial"[Title]) NOT ("animals"[MeSH Terms] NOT "humans"[MeSH Terms]))) OR ((("Breast Neoplasms"[MeSH Terms] OR "breast cancer"[Title/Abstract]) AND ("breast neoplasms/secondary"[MeSH Terms] OR "Neoplasm Metastasis"[MeSH Terms] OR "neoplasm recurrence, local"[MeSH Terms] OR "metast*"[Title/Abstract] OR "advanced"[Title/Abstract] OR "reccurren*"[Title/Abstract]) AND ("Ado-Trastuzumab Emtansine"[MeSH Terms] OR "Trastuzumab Emtansine"[Title/Abstract] OR ("Trastuzumab"[MeSH Terms] AND "pertuzumab"[Supplementary Concept] AND ("Taxoids"[MeSH Terms] OR "taxoid*"[Title/Abstract] OR "taxane*"[Title/Abstract]))) AND ("English"[Language] OR "Japanese"[Language]) AND ("Meta-Analysis"[Publication Type] OR "Systematic"[Filter])))</p>
<p>FRQ12</p>	<p>HER2陽性転移・再発乳癌に対する三次以降の治療で推奨される治療は何か？</p>	<p>"breast neoplasms/drug therapy"[MeSH Terms] AND ("breast neoplasms/secondary"[MeSH Terms] OR "Neoplasm Metastasis"[MeSH Terms] OR "neoplasm recurrence, local"[MeSH Terms] OR "metasta*"[Title/Abstract] OR "advanced"[Title/Abstract] OR "reccurren*"[Title/Abstract]) AND ("receptor, erbb 2"[MeSH Terms] OR "erbB-2"[Title/Abstract] OR "her2"[Title/Abstract] OR "her-2"[Title/Abstract]) AND ("antibodies, monoclonal, humanized/therapeutic use"[MeSH Terms] OR "antineoplastic combined chemotherapy protocols/therapeutic use"[MeSH Terms] OR "antineoplastic agents/therapeutic use"[MeSH Terms]) AND "Antineoplastic Agents"[Pharmacological Action] AND 2016/01/01:2021/03/31[Date - Publication] AND ("English"[Language] OR "Japanese"[Language]) AND ("Meta-Analysis"[Publication Type] OR "Systematic"[Filter])</p>

CQ29	HER2陽性・ホルモン受容体陽性転移・再発乳癌に対して内分泌療法単独や抗HER2療法と内分泌療法併用は勧められるか？	<p>"breast neoplasms/drug therapy"[MeSH Terms] AND ("breast neoplasms/secondary"[MeSH Terms] OR "Neoplasm Metastasis"[MeSH Terms] OR "neoplasm recurrence, local"[MeSH Terms] OR "metastatic"[Title/Abstract] OR "advanced"[Title/Abstract] OR "reccurren*"[Title/Abstract]) AND ("receptor, erbb 2"[MeSH Terms] OR "ErbB Receptors"[MeSH Terms] OR "phosphoproteins"[MeSH Terms:noexp] OR "proto oncogene proteins"[MeSH Terms:noexp] OR "erbB-2"[Title/Abstract] OR "her2"[Title/Abstract] OR "her-2"[Title/Abstract]) AND ("estrogen antagonists"[MeSH Terms] OR "estrogen antagonists"[Pharmacological Action] OR "antineoplastic agents, hormonal"[MeSH Terms] OR "antineoplastic agents hormonal"[Pharmacological Action] OR "gonadotropin releasing hormone"[MeSH Terms] OR "aromatase inhibitors"[MeSH Terms] OR "aromatase inhibitors"[Pharmacological Action] OR ("estrogen antagonists"[MeSH Terms] OR "estrogen antagonists"[Pharmacological Action] OR "antineoplastic agents, hormonal"[MeSH Terms] OR "antineoplastic agents hormonal"[Pharmacological Action] OR "gonadotropin releasing hormone"[MeSH Terms] OR "aromatase inhibitors"[MeSH Terms] OR "aromatase inhibitors"[Pharmacological Action]) AND "antibodies, monoclonal, humanized"[MeSH Terms]) OR "Antineoplastic Combined Chemotherapy Protocols"[MeSH Terms]) AND ("English"[Language] OR "Japanese"[Language]) AND 2016/01/01:2021/03/31[Date - Publication] AND (("randomized controlled trial"[Publication Type] OR "controlled clinical trial"[Publication Type] OR "Randomized"[Title/Abstract] OR "Placebo"[Title/Abstract] OR "clinical trials as topic"[MeSH Terms:noexp] OR "randomly"[Title/Abstract] OR "Trial"[Title]) NOT ("animals"[MeSH Terms] NOT "humans"[MeSH Terms]))</p>
CQ30	転移・再発トリプルネガティブ乳癌に対してプラチナ製剤は勧められるか？	<p>("triple negative breast neoplasms"[MeSH Terms] OR (("breast neoplasms"[MeSH Terms] OR "breast cancer"[Title/Abstract]) AND "triple negative"[Title/Abstract])) AND ("carboplatin"[MeSH Terms] OR "cisplatin"[MeSH Terms] OR "carboplatin"[Title/Abstract] OR "platinum"[Title/Abstract]) AND 2018/01/01:2021/03/31[Date - Publication] AND ("English"[Language] OR "Japanese"[Language]) AND (("randomized controlled trial"[Publication Type] OR "controlled clinical trial"[Publication Type] OR "randomized"[Title/Abstract] OR "placebo"[Title/Abstract] OR "clinical trials as topic"[MeSH Terms:noexp] OR "randomly"[Title/Abstract] OR "trial"[Title]) NOT ("animals"[MeSH Terms] NOT "humans"[MeSH Terms]))</p>

CQ31	転移・再発乳癌に対してPD-1/PD-L1阻害薬は勧められるか？	(("Breast Neoplasms"[MeSH Terms] OR "breast cancer"[Title/Abstract]) AND ("advanced"[Title/Abstract] OR "metastatic"[Title/Abstract] OR "recurren*"[Title/Abstract] OR "Neoplasm Metastasis"[MeSH Terms] OR "neoplasm recurrence, local"[MeSH Terms]) AND ("atezolizumab"[Text Word] OR "pembrolizumab"[Text Word]) AND ("English"[Language] OR "Japanese"[Language]) AND 2020/01/01:2021/03/31[Date - Publication] AND (("randomized controlled trial"[Publication Type] OR "controlled clinical trial"[Publication Type] OR "randomized"[Title/Abstract] OR "placebo"[Title/Abstract] OR "clinical trials as topic"[MeSH Terms:noexp] OR "randomly"[Title/Abstract] OR "trial"[Title]) NOT ("animals"[MeSH Terms] NOT "humans"[MeSH Terms]))) OR (("Breast Neoplasms"[MeSH Terms] OR "breast cancer"[Title/Abstract]) AND ("advanced"[Title/Abstract] OR "metastatic"[Title/Abstract] OR "recurren*"[Title/Abstract] OR "Neoplasm Metastasis"[MeSH Terms] OR "neoplasm recurrence, local"[MeSH Terms]) AND ("atezolizumab"[Text Word] OR "pembrolizumab"[Text Word]) AND ("English"[Language] OR "Japanese"[Language]) AND 2020/01/01:2021/03/31[Date - Publication] AND ("systematic"[Filter] OR "Meta-Analysis"[Publication Type]))
CQ32	生殖細胞系列BRCA病的バリエントを有する進行・再発乳癌患者の薬物療法として、PARP阻害薬は推奨されるか？	("Breast Neoplasms/drug therapy"[MH] OR "Carcinoma, Intraductal, Noninfiltrating/drug therapy"[MH] OR "Carcinoma, Ductal, Breast/drug therapy"[MH] OR "Carcinoma, Lobular/drug therapy"[MH] OR "Breast Carcinoma In Situ/drug therapy"[MH]) AND (("BRCA1 Protein"[MH] OR "BRCA1 protein, human" [NM]) OR ("BRCA2 Protein"[MH] OR "BRCA2 protein, human" [NM]) OR ("Genes, BRCA1"[MH] OR "Genes, BRCA2"[MH])) AND ("Poly(ADP-ribose) Polymerase Inhibitors"[MH] OR "Poly(ADP-ribose) Polymerase Inhibitors" [PA] OR "mefuparib hydrochloride" [NM]) AND (english[LA] OR japanese[LA]) AND ("2016/01"[DP] : "2021/03"[DP])
FRQ13	生殖細胞系列BRCA病的バリエントを有する進行・再発乳癌患者に対してプラチナ製剤は推奨されるか？	"Breast Neoplasms/drug therapy"[MH] AND (("BRCA1 Protein"[MH] OR "Genes, BRCA1"[MH] OR "BRCA1 protein, human" [NM]) OR ("Genes, BRCA2"[MH] OR "BRCA2 Protein"[MH] OR "BRCA2 protein, human" [NM] )) AND ("Platinum Compounds"[MH] OR "Carboplatin"[MH] OR "Oxaliplatin"[MH] OR "Organoplatinum Compounds"[MH] AND ("2016"[DP] : "2018"[DP]))) AND (english[LA] OR japanese[LA]) AND ("2016/01"[DP] : "2021/03"[DP])
FRQ14	転移・再発乳癌に対して、治癒を目指した治療を行うことは勧められるか？	"breast neoplasms/drug therapy"[MeSH Terms] AND ("advanced"[Title/Abstract] OR "metastatic"[Title/Abstract] OR "recurren*"[Title/Abstract] OR "Neoplasm Metastasis"[MeSH Terms] OR "neoplasm recurrence, local"[MeSH Terms]) AND "disease free survival"[MeSH Terms] AND ("tapering"[Text Word] OR "reduction*"[Title/Abstract] OR "cure"[Title/Abstract]) AND ("English"[Language] OR "Japanese"[Language]) AND 0001/01/01:2021/03/31[Date - Publication]

FRQ15	<p>転移・再発乳癌に対して、化学療法奏効後に内分泌療法による維持療法は勧められるか？</p>	<p>((("breast neoplasms/secondary"[MeSH Terms] OR "Neoplasm Metastasis"[MeSH Terms] OR "neoplasm recurrence, local"[MeSH Terms] OR "metasta*"[Title/Abstract] OR "advanced"[Title/Abstract] OR "reccurren*"[Title/Abstract]) AND ("breast neoplasms/drug therapy"[MeSH Terms] OR "breast cancer"[Title]) AND "Maintenance"[Text Word] AND ("antineoplastic agents, hormonal"[MeSH Terms] OR "antineoplastic agents hormonal"[Pharmacological Action] OR ("Aromatase Inhibitors"[MeSH Terms] OR "Aromatase Inhibitors"[Pharmacological Action]) OR ("Tamoxifen"[MeSH Terms] OR "Tamoxifen"[Text Word]) OR "Fulvestrant"[Text Word] OR "Bevacizumab"[Text Word]) AND 2016/01/01:2021/03/31[Date - Publication] AND ("English"[Language] OR "Japanese"[Language])) OR ((("breast neoplasms/secondary"[MeSH Terms] OR "Neoplasm Metastasis"[MeSH Terms] OR "neoplasm recurrence, local"[MeSH Terms] OR "metasta*"[Title/Abstract] OR "advanced"[Title/Abstract] OR "reccurren*"[Title/Abstract]) AND ("breast neoplasms/drug therapy"[MeSH Terms] OR "breast cancer"[Title]) AND ("antineoplastic agents, hormonal"[MeSH Terms] OR "antineoplastic agents hormonal"[Pharmacological Action] OR ("Aromatase Inhibitors"[MeSH Terms] OR "Aromatase Inhibitors"[Pharmacological Action]) OR ("Tamoxifen"[MeSH Terms] OR "Tamoxifen"[Text Word]) OR "Fulvestrant"[Text Word] OR "Bevacizumab"[Text Word]) AND 2016/01/01:2021/03/31[Date - Publication] AND ("English"[Language] OR "Japanese"[Language]) AND ("Randomized Controlled Trial"[Publication Type] OR "systematic"[Filter] OR "Meta-Analysis"[Publication Type]))))</p>
FRQ16	<p>転移・再発高齢者乳癌に対する薬物療法として何が推奨されるか？</p>	<p>"breast neoplasms/drug therapy"[MeSH Terms] AND ("Aged"[MeSH Terms] OR "elderly"[Title/Abstract]) AND ("Neoplasm Metastasis"[MeSH Terms] OR "neoplasm recurrence, local"[MeSH Terms] OR "metasta*"[Title/Abstract] OR "recurren*"[Title/Abstract] OR "breast neoplasms/secondary"[MeSH Terms] OR "advanced"[Title/Abstract]) AND ("Antineoplastic Agents"[MeSH Terms:noexp] OR "Antineoplastic Agents"[Pharmacological Action] OR "antineoplastic agents, hormonal"[MeSH Terms] OR "chemotherapy, adjuvant"[MeSH Terms:noexp] OR "Adjuvant"[Title/Abstract] OR "antineoplastic combined chemotherapy protocols"[MeSH Terms]) AND 2016/01/01:2021/03/31[Date - Publication] AND ("English"[Language] OR "Japanese"[Language]) AND ("Meta-Analysis"[Publication Type] OR "Systematic"[Filter])</p>
FRQ17	<p>転移・再発男性乳癌に対する薬物療法は何が推奨されるか？</p>	<p>((("Breast Cancer"[Tiab] AND Men[Tiab]) OR "Male breast cancer"[Tiab] OR "Male breast carcinoma"[Tiab] OR Breast Neoplasms, Male/drug therapy[MH]) AND (("Molecular Targeted Therapy"[Mesh]) OR ("endocrine therapy"[TIAB] OR "Antineoplastic Combined Chemotherapy Protocols"[MH] OR "Antineoplastic Agents, Hormonal"[MH] OR tamoxifen[MH] OR "Aromatase Inhibitors"[MH] OR fulvestrant[MH]))) AND ("0001/01/01"[DP] : "2021/3/31"[DP]) AND ("English"[LA] OR "Japanese"[LA]))</p>
FRQ18	<p>局所・領域再発切除術後に薬物療法は勧められるか？</p>	<p>breast neoplasms[MH] AND "neoplasm recurrence, local"[MH] AND "mastectomy"[MH] AND (chemotherapy, adjuvant[MH] OR adjuvant[TIAB] OR postoperative[TIAB]) AND ("Drug Therapy"[MH] OR "drug therapy" [SH]) AND (english[LA] OR japanese[LA]) AND ("2016/01"[DP] : "2021/03"[DP])</p>

FRQ19	乳癌脳転移および髄膜播種に抗悪性腫瘍薬は勧められるか？	((((("Breast Neoplasms/pathology"[MH]) AND (("Brain Neoplasms/secondary"[MH]) OR "Meningeal Neoplasms/secondary"[MH])) OR (((("Breast Neoplasms"[MH]) AND (("Brain Neoplasms"[MH]) OR "Meningeal Neoplasms"[MH])) AND ("Neoplasm Metastasis"[MH]))) AND (("Antineoplastic Agents"[MH] OR "Antineoplastic Agents" [PA]) OR ("Drug Therapy"[MH] OR "drug therapy" [SH]))) AND ((english[LA] OR japanese[LA]) AND ("2016/01"[DP] : "2021/03"[DP]))) AND ((Systematic Review[PT] OR systematic[SB] OR Meta-Analysis[PT]))
BQ11	アロマターゼ阻害薬使用患者における骨粗鬆症の予防・治療に骨吸収抑制薬（ビスホスホネート、デノスマブ）は推奨されるか？	(("Breast Neoplasms"[MeSH Terms] OR "Breast cancer"[Title/Abstract]) AND ("Neoplasm Metastasis"[MeSH Terms] OR "neoplasm recurrence, local"[MeSH Terms] OR "metas*"[Title/Abstract] OR "bone neoplasms/secondary"[MeSH Terms] OR "advanced"[Title/Abstract] OR "recurren*"[Title/Abstract]) AND ("denosumab"[MeSH Terms] OR "denosumab"[Title/Abstract] OR "diphosphonates"[MeSH Terms] OR "Bisphosphonate"[Title/Abstract] OR ("Bone Density Conservation Agents"[MeSH Terms] OR "Bone Density Conservation Agents"[Pharmacological Action])) AND ("Aromatase Inhibitors"[MeSH Terms] OR "Aromatase Inhibitors"[Pharmacological Action] OR "aromatase"[Title/Abstract]) AND 2016/01/01:2021/03/31[Date - Publication] AND ("English"[Language] OR "Japanese"[Language]) AND ("systematic"[Filter] OR "Meta-Analysis"[Publication Type])) OR (((("Breast Neoplasms"[MeSH Terms] OR "Breast cancer"[Title/Abstract]) AND ("Neoplasm Metastasis"[MeSH Terms] OR "neoplasm recurrence, local"[MeSH Terms] OR "metas*"[Title/Abstract] OR "bone neoplasms/secondary"[MeSH Terms] OR "advanced"[Title/Abstract] OR "recurren*"[Title/Abstract]) AND ("denosumab"[MeSH Terms] OR "denosumab"[Title/Abstract] OR "diphosphonates"[MeSH Terms] OR "Bisphosphonate"[Title/Abstract] OR ("Bone Density Conservation Agents"[MeSH Terms] OR "Bone Density Conservation Agents"[Pharmacological Action])) AND ("Aromatase Inhibitors"[MeSH Terms] OR "Aromatase Inhibitors"[Pharmacological Action] OR "aromatase"[Title/Abstract]) AND 2016/01/01:2021/03/31[Date - Publication] AND ("English"[Language] OR "Japanese"[Language]) AND (("randomized controlled trial"[Publication Type] OR "controlled clinical trial"[Publication Type] OR "randomized"[Title/Abstract] OR "placebo"[Title/Abstract] OR "clinical trials as topic"[MeSH Terms:noexp] OR "randomly"[Title/Abstract] OR "trial"[Title]) NOT ("animals"[MeSH Terms] NOT "humans"[MeSH Terms])))
FRQ20	乳癌診療において次世代シーケンサー等を用いた遺伝子パネル検査は有用か？	((((("Breast Neoplasms"[Mesh] OR "breast cancer"[TI]) AND (("Precision Medicine"[Mesh]) OR ("Molecular Targeted Therapy"[Mesh]) OR ("High-Throughput Nucleotide Sequencing"[Mesh]) OR ("next generation sequencing"[TIAB]))) NOT ("animals"[MeSH Terms] NOT "humans"[MeSH Terms]) AND (2018/01/01[PDAT] : 2021/3/31[PDAT]) AND (English[LA] OR Japanese[LA])) AND (systematic[SB] OR Meta-Analysis[PT]))
FRQ21	乳腺悪性葉状腫瘍の遠隔転移に対して薬物療法は進められるか？	((((Breast neoplasms[MH] OR "Breast"[Tiab]) AND ("drug therapy"[TW] OR "Antineoplastic Agents"[Mesh] OR "Antineoplastic Agents"[Pharmacological Action] OR chemotherapy[TW]) AND (Phyllodes Tumor[MH] OR "Phyllodes"[Tiab])) NOT (Animals[MH] NOT Humans[MH]) AND ("2018/01/01"[DP] : "2021/3/31"[DP]) AND ("English"[LA] OR "Japanese"[LA]))